

CLEAN COPY OF PENDING CLAIMS
November 5, 2001

12. A multispecific antibody prepared by the method comprising:

(a) expressing in a host cell a first polypeptide comprising a first heavy chain variable domain, a first or second light chain variable domain, and a first multimerization domain, wherein the first and second light chain variable domains have at least 80% amino acid sequence identity, and wherein a first binding domain is formed by the first heavy chain variable domain and the first or second light chain variable domain;

(b) expressing in the host cell a second polypeptide comprising a second heavy chain variable domain, the first or the second light chain variable domain, and a second multimerization domain, wherein a second binding domain is formed by the second heavy chain variable domain and the first or second light chain variable domain, and wherein the first and second binding domains bind different antigens;

(c) allowing the first and second polypeptides to dimerize by interaction of the first and second multimerization domains to form a multispecific antibody; and

(d) recovering the multispecific antibody from the host cell.

13. A multispecific antibody comprising a first polypeptide and at least one additional polypeptide, the multispecific antibody comprising:

(a) the first polypeptide which comprises a first heavy chain variable domain, a first or second light chain variable domain, and a first multimerization domain, wherein the first and second light chain variable domains have at least 80% amino acid sequence identity, and wherein a first binding domain is formed by the first heavy chain variable domain and the first or second light chain variable domain;

second light chain variable domain, and wherein the first and second binding domains bind different antigens;

(c) the first and second polypeptides dimerize by interaction of the first and second multimerization domains to form a multispecific antibody.

14. The multispecific antibody of claim 13, wherein the nucleic acid encoding the first polypeptide or the nucleic acid encoding the additional polypeptide, or both, has been altered from the original nucleic acid to encode the multimerization domain or a portion thereof.

16. The multispecific antibody of claim 14 wherein the multimerization domains of the first and an additional polypeptide comprise a protuberance and cavity, respectively.

17. The multispecific antibody of claim 16 wherein the protuberance and cavity are generated by alterations in which naturally occurring amino acids are imported into the first and additional polypeptides.

18. A composition comprising the multispecific antibody of claim 13 and a carrier.

31. The multispecific antibody of claim 13 wherein the antibody is anti-CE-R/anti-HER3.

33. The composition according to claim 18, wherein the multispecific antibody is anti-Ob-R/anti-HER3.

34. The multispecific antibody of claim 13, wherein the first and second light chain variable domains have at least 90 amino acid

sequence identity.

36. The multispecific antibody of claim 13, wherein the first and second light chain variable domains have at least 98% amino acid sequence identity.

37. The multispecific antibody of claim 13, wherein the first and second light chain variable domains have at least 99% amino acid sequence identity.

38. The multispecific antibody of claim 13, wherein the first and second light chain variable domains have identical amino acid sequences.